29 August 2023 in Autoimmunity Reviews
The therapeutic landscape of rheumatoid arthritis (RA) has rapidly evolved in the last few decades. At the same time, recommendations for the management of the disease suggest to minimize glucocorticoids (GCs) use in RA patients. Major concerns are the risk of long-term adverse events and the difficulties in discontinuing GCs once initiated. However, real-world data show that up to 50% of RA patients continue to take GCs during the disease course. Adverse events of GCs usually occur after a long-term use, which can limit the generalizability of randomized controlled trials (RCTs) proving no or minimal harm. Observational studies show conflicting results regarding the safety of GSs and are subjected to a high risk of bias, including indication bias. Thus, whether or not GCs should be used in the management of RA is still a matter of debate. The main reasons to support GCs use are the ability to rapidly suppress joint inflammation while waiting for the full effect of conventional synthetic disease-modifying antirheumatic drugs (csDMARD) and the acknowledged efficacy on radiographic progression in early RA. The main reasons to avoid GCs use in RA are that their potential risks may outweigh their benefits and there is no agreement on the minimal daily dosage of GC which can be considered safe.
22 August 2025 in Annals of the Rheumatic Diseases
We aimed to characterise the synovial pathology of refractory rheumatoid arthritis (RA) by comparing two hypothesised clinical phenotypes-persistent inflammatory refractory RA (PIRRA) and noninflammatory refractory RA (NIRRA)-against nonrefractory RA (NORRA). We conducted a prospective, observational cohort study at two academic rheumatology centres. Adult patients with established RA and active disease (Clinical Disease Activity Index >10) underwent ultrasound-guided synovial tissue biopsies in accordance with European Alliance of Associations for Rheumatology-Outcome Measures in Rheumatology guidelines. Based on the Physician Global Assessment (>2/10) and C-reactive protein (>5 mg/L) thresholds, biological and targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs)-inadequate responders patients were classified as PIRRA or NIRRA, whereas b/tsDMARD-naïve were designated NORRA. Histopathological assessments included the Krenn Synovitis Score (KSS) and immunohistochemistry pathotype evaluation (lympho-myeloid, diffuse-myeloid, pauci-immune/fibroid). Of the 93 biopsied patients, 43 were PIRRA, 21 NIRRA, and 29 NORRA. NIRRA had lower KSS (P = .012), lymphoid aggregates (P < .001) and predominantly pauci-immune/fibroid pathotype (n = 21/43, 47.6%), whereas PIRRA displayed more lympho- and diffuse-myeloid pathotypes, coupled with higher inflammatory markers and ultrasound-power Doppler scores. The relative risk of having pauci-immune fibroid synovitis for NIRRA was 1.6 (95% CI 1.2 to 2.9, P = .006), indicating a statistically significant increase in risk compared to PIRRA. Despite having similar overall disease activity scores, NIRRA patients reported significantly greater pain (P = .005) and higher opioid use (P = .015) than PIRRA, and worse health-related quality of life than PIRRA or NORRA, underscoring noninflammatory mechanisms. Our findings demonstrate distinct synovial and clinical phenotypes in refractory RA. Although PIRRA appears driven by active synovial inflammation and immune cell infiltration, NIRRA involves predominantly pauci-immune/fibroid histology with significant noninflammatory contributors to disease burden.
1 September 2025 in Mayo Clinic Proceedings
To explore the influence of the physician's sex on long-term outcomes in patients with rheumatoid arthritis (RA) undergoing targeted therapy. A prospective, single-center cohort study of adult RA patients treated with biologic and targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) was conducted between 2014 and 2022. The physician's sex was the main exposure. The primary outcome was disease activity score in 28 joints (DAS28), and the secondary outcomes were DAS28 subcomponents and glucocorticoid use. The association between the physician's sex and outcomes was assessed by generalized estimating equations. Covariates were selected through regularization techniques. We included 1151 patients (81% female) with a mean age of 57 years, a mean disease duration of 14 years, and a median observation of 4 years. At the time of inclusion, 68% of the patients had moderate-high DAS28. Management by female physicians yielded significantly lower mean DAS28 (2.80 [95% CI, 2.65 to 2.97] vs 3.00 [95% CI, 2.87 to 3.19]; P=.004) and a higher likelihood of DAS28 remission (adjusted odds ratio, 1.84 [95% CI, 1.16 to 2.17]; P<.0001) compared with male physicians. Secondary outcome analyses also found lower C-reactive protein level (2.5 vs 3.5 mg/L; P<.0001) and swollen joint count in 28 joints (0.9 vs 1.4; P<.0001) and no significant differences in glucocorticoid use. Sensitivity analyses found that the effect of the physician's sex was mostly directed at male patients. The sex of the physician can significantly influence disease control in patients with RA, with female rheumatologists achieving better outcomes in terms of disease activity and remission.
19 December 2025 in Arthritis Research & Therapy
Treatment of rheumatoid arthritis (RA) frequently requires Janus kinase inhibitors (JAKi) and biologic DMARDs (bDMARDs) with other mechanisms of action (OMA) after tumour necrosis factor inhibitors (TNFi) failure. Comparative safety data between JAKis and OMA in TNFi-inadequate responders (TNFi-IR) remain limited. To evaluate and compare safety profiles of JAKis versus OMA in TNFi-IR RA patients. A retrospective cohort study followed 305 RA patients (163 JAKis; 142 OMA) previously treated with TNFi for up to 24 months. Incidence rates (IR) of adverse events (AEs) per 100 patient-years (PY) and incidence rate ratios (IRR) adjusted for disease activity and previous bDMARD exposure were calculated using Poisson regression. At baseline, OMA patients had higher disease activity (DAS28-CRP = 4.5 vs. 3.8), whereas comorbidities and other baseline characteristics were similar. Overall, AE incidence was higher with OMA (IR 111.6/100 PY) compared to JAKis (IR 65.3/100 PY; adjusted IRR 1.67, 95% CI 1.22-2.31). Serious AEs occurred more frequently with OMA (IR 11.7/100 PY) versus JAKis (IR 7.9/100 PY; adjusted IRR 0.41, 95% CI 0.18-0.95). Infection rates were comparable; herpes zoster occurred exclusively in the JAKi group during the initial year. Venous thromboembolism, cardiovascular events, and malignancies were rare and similar between groups. In RA patients with inadequate response to TNFis, JAKis and OMA showed comparable safety profiles over 24 months. Serious AEs were numerically higher with OMA; herpes zoster was more frequent with JAKis. No new significant safety signals emerged.
17 November 2025 in Rheumatology
Objectives: To evaluate the impact of oral low-dose glucocorticoids (GCs) on the effectiveness of Janus kinase inhibitors (JAKis) compared with non-TNF-targeted bDMARDs (other mechanisms of action [OMA] including tocilizumab, abatacept and rituximab) in RA patients with inadequate response to TNF inhibitors (TNFi-IRs). Methods: Single-centre, retrospective cohort study. The primary outcome was the good EULAR response at 6, 12 and 24 months. Secondary outcomes included treatment discontinuation and remission rates. Statistical analyses included structural equation modeling (SEM), competing risks analysis and linear mixed-effects models. Results: The study included 299 patients (JAKi = 161, OMA = 138). Baseline GC use was similar between the groups (JAKi = 66.5%, OMA = 76%; P = 0.089; mean (SD) daily dose 4.4 (5.5) vs 4.9 (4.5) mg/d; P = 0.355). The proportion of GC users treated with JAKi or OMA at 6, 12 and 24 months was 49.7% vs 63.8% (P = 0.036), 37.3% vs 40.6% (P = 0.161) and 27.3% vs 34.1% (P = 0.430). No statistically significant differences in GC dose reduction were observed between the two groups across any time interval. The EULAR response improved at 24 months, with JAKi outperforming OMA (SEM; P = 0.040). GC dosage at 6 months negatively affected the 24-month outcome (β = −0.456, P = 0.020). DAS28-CRP remission was more frequent in the JAKi group (P < 0.05), while discontinuation rates were similar (HR = 1.49, P = 0.34). Conclusion: JAKi did not show superiority over OMA regarding steroid-sparing effects; however, JAKi yielded higher remission rates. Exposure to GC at 6 months predicted poorer 24-month outcomes.
11 September 2024 in Rheumatology
Mariangela Salvato, Francesca Frizzera, Kiren Khalid, Sara Bindoli, Marco Cola, Marco Trevenzoli, Marny Fedrigo, Annalisa Angelini, Andrea Doria, Alessandr